KUALA LUMPUR: Alpha IVF Group Bhd posted a record revenue of RM198.6mil for the financial year ended May 31, 2026 (FY26), supported by continued growth in its Malaysia operations, although higher expansion costs weighed on earnings.
Profit after tax and minority interests (PATMI) eased to RM53.6mil, or earnings per share of 1.10 sen, down from RM57.5mil, or 1.18 sen a year ago, as the fertility care specialist continued investing in its regional expansion.
Malaysia remained the group's largest contributor at RM178.8mil, or 90% of total revenue. Singapore contributed RM16.1mil, while its operations in the Philippines and Indonesia generated RM2mil and RM1.8mil, respectively.
For the fourth quarter ended May 31, 2026 (4Q26), PATMI fell to RM13.9mil, or 0.29 sen from RM16.1mil, or 0.33 sem a year prior, despite revenue rising to RM52.1mil from RM50mil.
Alpha IVF declared a second interim dividend of 0.60 sen per share, bringing the total dividend for FY26 to 1.10 sen per share.
The payout amounts to RM53.5mil, representing 99.7% of FY26 PATMI, exceeding its dividend policy of distributing at least 60% of annual PATMI.
Group managing director Datuk Dr Colin Lee Soon Soo said the group's Malaysia operations continued to underpin performance, with both local and foreign patient segments recording healthy growth.
“PATMI was slightly lower than last year, mainly due to high expansion costs as we continue to invest for our long-term growth initiatives. The investments we are making today are expected to strengthen our regional presence and support the group’s growth over the coming years.
“Looking ahead, we will continue to focus on delivering high success rates and quality fertility care, expanding our patient base, and creating sustainable value for our shareholders,” Lee said.
During FY26, Alpha IVF opened new fertility centres in Kota Kinabalu and Manila, increasing its network to six full-fledged IVF centres.
The group expects to open four more centres in FY27, comprising one each in Malaysia and the Philippines, and two in Indonesia, expanding its network to 10 centres.
Lee said patient demand at the new centres has been encouraging and expects expansion-related costs to gradually normalise as the new facilities mature, supporting future profit growth alongside revenue expansion.
